The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
First for Women on MSN19h
Ozempic Now FDA-Approved for Kidney Disease-Here's What to KnowGLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...
Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback